PPP1R13B: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: PPP1R13B

NCBI ID: G23368

PPP1R13B

PPP1R13B: A Promising Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of individuals worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with the majority of cases being caused by non-cancer pain. Chronic pain can be caused by various underlying conditions, such as fibromyalgia, rheumatoid arthritis, and neuropathic pain. These conditions can significantly impact an individual's quality of life, leading to functional limitations, disability, and even depression.

PPP1R13B, a protein known as the protamineuronylated protein PPP1R13B (Pro-P85), has been identified as a potential drug target and biomarker for the management of chronic pain. In this article, we will discuss the structure, function, and potential therapeutic applications of PPP1R13B, as well as its potential as a drug target and biomarker for chronic pain.

Structure and Function

PPP1R13B is a 21-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain contains a putative G protein-coupled receptor (GPCR) domain, which is responsible for the protein's interaction with ligands. The C-terminal domain contains a unique structural feature, known as a protamineuronylated side chain, which is a unique modification found in proteins that plays a crucial role in protein stability and modifies the protein's function.

PPP1R13B functions as a negative regulator of the pain signaling pathway. It is involved in the regulation of nociceitin, a potent pain transmitter that is involved in the development of chronic pain. PPP1R13B plays a crucial role in the negative regulation of nociceitin signaling by modulating the activity of TrkB, a GPCR that is involved in the signaling pathway.

PPP1R13B's role in pain management is due to its unique structure and function. Its N-terminal domain, which contains a GPCR domain, allows it to interact with various ligands, including nociceitin, leading to its involvement in pain signaling. Its C-terminal domain, with its unique protamineuronylated side chain, plays a crucial role in modifying the protein's stability and function, allowing it to remain active in the presence of various stressors, including pain stimuli.

In addition to its role in pain management, PPP1R13B has also been shown to have potential as a biomarker for the assessment of chronic pain. The expression and distribution of PPP1R13B have been observed in various pain-related tissues, including brain, spinal cord, and peripheral tissues, suggesting its potential as a biomarker for the assessment of chronic pain.

Potential Therapeutic Applications

The identification of PPP1R13B as a potential drug target for chronic pain management has significant implications for the treatment of chronic pain. PPP1R13B is involved in the regulation of nociceitin signaling, which is involved in the development of chronic pain. Therefore, compounds that can modulate PPP1R13B activity could potentially be effective in the treatment of chronic pain.

One of the potential therapeutic applications of PPP1R13B is its potential as an antagonist of nociceitin. Nociceitin is a potent pain transmitter that is involved in the development of chronic pain. By modulating

Protein Name: Protein Phosphatase 1 Regulatory Subunit 13B

Functions: Regulator that plays a central role in regulation of apoptosis via its interaction with p53/TP53 (PubMed:11684014, PubMed:12524540). Regulates TP53 by enhancing the DNA binding and transactivation function of TP53 on the promoters of proapoptotic genes in vivo

The "PPP1R13B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R13B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets